

Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status

Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Auro Pharma Inc.	Auro-Terbinafine	Lamisil	terbinafine HCl	250mg	tablet	02320134
Mylan Pharmaceuticals ULC	Mylan-Zolmitriptan	Zomig	zolmitriptan	2.5mg	FC tablet	02369036
Pharmascience Inc.	Pms-Zolmitriptan	Zomig	zolmitriptan	2.5mg	FC tablet	02324229
Pharmascience Inc.	Pms-Zolmitriptan ODT	Zomig Rapimelt	zolmitriptan	2.5mg	ODT tablet	02324768
Sandoz Canada Inc.	Sandoz Zolmitriptan ODT	Zomig Rapimelt	zolmitriptan	2.5mg	ODT tablet	02362996
Sandoz Canada Inc.	Sandoz Zolmitriptan	Zomig	Zolmitriptan	2.5mg	FC tablet	02362988

Teva Canada Limited	Teva-Olanzapine	Zyprexa	olanzapine	20mg	FC tablet	02359707
---------------------	-----------------	---------	------------	------	-----------	----------

Updated: July 22, 2011

